经房间隔入路经导管二尖瓣置换术治疗二尖瓣环钙化:ENCIRCLE MAC注册研究1年结果
ENCIRCLE MAC注册研究为前瞻性、多中心、单臂研究,纳入症状性二尖瓣环钙化相关二尖瓣功能障碍且不适合外科手术或经导管修复的患者。364例筛查患者中100例尝试经房间隔TMVR,93例成功植入SAPIEN M3瓣膜。1年全因死亡或心衰住院的Kaplan-Meier估计为33.6%,全因死亡21.1%,心衰住院19.4%;植入患者中98.5%实现MR≤1+,症状、生活质量和6分钟步行距离改善持续至1年。
要点
- 经房间隔TMVR在经选择的MAC相关MVD患者中1年全因死亡或心衰住院估计为33.6%。
- 植入患者1年MR≤1+达98.5%,NYHA分级、KCCQ评分和6分钟步行距离改善持续。
- 致残性卒中5.1%、临床显著LVOT梗阻4.8%、瓣膜血栓2.3%、需输血或二尖瓣再干预的溶血9.2%。
核心结论
- 在经仔细选择、不适合外科手术或经导管修复的症状性MAC相关MVD患者中,经房间隔TMVR与持续MR减少及症状和生活质量改善相关至1年,支持其作为治疗路径考虑。
研究设计与样本
- ENCIRCLE MAC注册研究为前瞻性、多中心、单臂研究,纳入症状性MAC相关MVD且不适合外科手术或经导管修复的患者。
- 364例筛查患者中100例尝试TVMR,93例成功植入瓣膜;平均年龄76.1±9.2岁,51.0%为男性,73.0%为NYHA III/IV级,STS预测二尖瓣置换死亡风险均值8.4%±4.9%。
主要发现
- 1年全因死亡或心衰住院的Kaplan-Meier估计为33.6%(95%CI:25.0%-44.1%),全因死亡21.1%,心衰住院19.4%。
- 致残性卒中5.1%,临床显著左心室流出道梗阻4.8%,瓣膜血栓2.3%,需输血或二尖瓣再干预的溶血9.2%,二尖瓣再干预11.4%。
- 植入患者中1年MR≤1+达98.5%,NYHA功能分级、KCCQ总体总结评分和6分钟步行距离改善持续至1年。
关键数值与推荐
- 纳入标准包括≥中度至重度MR、重度二尖瓣狭窄或中度MR合并至少中度二尖瓣狭窄的症状性MAC相关MVD患者。
临床怎么用
- 对于经仔细选择、不适合外科手术或经导管修复的症状性MAC相关MVD患者,可考虑经房间隔TMVR作为治疗路径。
局限性
- 本研究为单臂研究,未设对照组,结果需在更广泛人群中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with symptomatic mitral valve dysfunction (MVD) and mitral annular calcification (MAC) represent one of the most challenging populations in structural heart disease. Advanced age, multiple comorbidities, extensive annular calcification, and unfavorable anatomy often preclude surgical mitral valve replacement or transcatheter repair, leaving many patients with limited treatment options. Whether fully percutaneous transseptal transcatheter mitral valve replacement (TMVR) can provide a meaningful treatment pathway for patients with MAC-related MVD remains uncertain. OBJECTIVES: The goal of this study was to evaluate 1-year clinical, echocardiographic, and patient-centered outcomes after transseptal TMVR with the SAPIEN M3 system in patients with symptomatic MAC-related MVD. METHODS: The ENCIRCLE (SAPIEN M3 System Transcatheter Mitral Valve Replacement Via Transseptal Access) trial MAC Registry is a prospective, multicenter, single-arm study that enrolled symptomatic patients with MAC-related MVD, including ≥ moderate to severe mitral regurgitation (MR), severe mitral stenosis, or combined moderate MR with at least moderate mitral stenosis, who were considered unsuitable for surgery or transcatheter repair. The primary endpoint was a nonhierarchical composite of all-cause mortality and heart failure hospitalization (HFH) at 1 year. RESULTS: Among 364 screened patients, TVMR was attempted in 100, and the valve was implanted in 93. Mean age was 76.1 ± 9.2 years, 51.0% were male, 73.0% were in NYHA functional class III/IV, and mean Society of Thoracic Surgeons Predicted Risk of Mortality score for mitral valve replacement was 8.4% ± 4.9%. At 1 year, the Kaplan-Meier estimate of all-cause mortality or HFH was 33.6% (95% CI: 25.0%-44.1%), with 21.1% all-cause mortality and 19.4% HFH. Disabling stroke occurred in 5.1%, clinically significant left ventricular outflow tract obstruction in 4.8%, valve thrombosis in 2.3%, hemolysis requiring transfusion or mitral valve reintervention in 9.2%, and mitral valve re-intervention in 11.4%. Among implanted patients, MR ≤1+ was achieved in 98.5% at 1 year. Improvements in NYHA functional class, Kansas City Cardiomyopathy Questionnaire Overall Summary score, and 6-minute walk distance were sustained through 1 year. CONCLUSIONS: In carefully selected patients with symptomatic MAC-related MVD unsuitable for surgery or transcatheter repair, transseptal TMVR with the SAPIEN M3 system was associated with sustained MR reduction and meaningful improvements in symptoms and quality of life through 1 year. These findings support consideration of transseptal TMVR as a treatment pathway for selected patients with MAC-related MVD.
引用
- Guerrero ME, Daniels DV, Whisenant B, et al. Transseptal Transcatheter Mitral Valve Replacement for Mitral Annular Calcification: ENCIRCLE MAC Registry 1-Year Outcomes. J Am Coll Cardiol. 2026. PMID: 42873164. doi:10.1016/j.jacc.2026.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。